Business Insights: Trends in Biotechnology Technology Transfer to 2014

Biotech companies are increasingly seeking technology transfer arrangements because investor funding remains difficult to find as we emerge from the economic downturn, finds Business Insights.
By: reports-research.com
 
Feb. 14, 2011 - PRLog -- Karen Mostert at Business Insights, comments: “The biotech industry has expanded rapidly resulting in a growing pipeline of products and at the end of 2009 more than 3,000 products were in clinical testing and 7,000 were undergoing clinical evaluation. However, biotech companies rarely have saleable products and rely on investor cash to maintain operations. As a result many are turning to technology transfer arrangements to fund continued operations.”

This coincides with such deals becoming increasingly attractive to Big Pharma which is facing complicated and increasingly interconnected disease targets, escalating research costs, fewer in-house R&D resources, increased regulatory scrutiny and demand for more clinical data.

Karen adds: “In 2008 there were 53 biotechnology transfer deals for human medicines. In 2009 this number more than doubled to 123. However, many deals fail as a result of failure to conduct proper due diligence, poor deal structure, management changes or simply goals not being met on time or budget or an inability to meet key scientific goals.”

The failure of biotechnology deals can have significant implications for both the technology developer and the sponsor, although consequences are usually more serious for the developer due to its often smaller size and greater reliance on a single revenue stream.

Karen concludes: “Despite the risk seemingly sitting with the biotech company, drug developers often seek out and acquire large numbers of new technologies and a high number of failures can in the long run greatly impact their competitiveness. As a result drug developers have developed best practice to reduce their exposure including the introduction of structured innovative deal terms and addressing international intellectual property challenges.”

One consequence of this is drug developers more closely aligning the technology valuations with actual market potential. As a result Business Insights predicts that deal value growth is expected to decline.


Business Insights: Building Biotech Technology Transfer Opportunities | Sponsor and developer strategies for success:
http://www.reports-research.com/market-surveys/building-b...

Business Insights: Further Market Data and Market Reports:
http://www.reports-research.com/market-surveys/business-i...

# # #

markt-studie.de founded in 2002 has emerged as a leading online portal for market surveys and market research in German speaking areas. Four years later the English language portal reports-research.com was introduced due to the extraordinary success of the portal. Again one year later estudio-mercado.es - the Spanish spoken portal - was founded. The objective of the three portals is to competently and efficiently support consultants and decision makers in management, sales and marketing in the search for worldwide market research. Prospective buyers can look into more than 60,000 market surveys from more than 200 international publishers, current market data for more than 6,000 branches worldwide, 10,000 company profiles as well as a free-of-charge research and recommendation service for individual market research.
End
Source:reports-research.com
Email:***@reports-research.com Email Verified
Tags:Biotechnology, Market Data, Analyses, Medical
Industry:Health, Medical
Location:Cologne - North Rhine-Westphalia - Germany
Account Email Address Verified     Disclaimer     Report Abuse
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share